# Lakefront Biotherapeutics American (LKFT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $28.49, market value $1.9 billion.

## Valuation
- **P/E (trailing): 2.7×** (5-yr avg 14.6×, 3-yr avg 14.6×). Lakefront Biotherapeutics American trades at 2.7× trailing earnings, well below its own five-year average of 14.6×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 1.6×**. Each dollar of revenue is priced at 1.6×.
- **Price / book: 9.9×**. The shares trade at 9.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -14.4%** (5-yr avg -16.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 36.7%**. The inverse of the P/E: 36.7% of the price is earned each year.

## Profitability
- **Gross margin: 97.5%**. Lakefront Biotherapeutics American keeps 97.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 61.6%**. 61.6% of revenue is left after running the business, an exceptional level.
- **Net margin: 28.9%**. 28.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 9.9%**. 9.9% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 17.5%**. Each dollar of assets produces 17.5% of profit.

## Growth
- **Revenue growth (1 yr): 303.5%** (3-yr 66.4%/yr, 5-yr 18.4%/yr). Revenue grew 303.5% over the last year, against 18.4% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 334.8%**. Earnings per share rose 334.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 20.15** (quick 20.15). Current assets cover the next year's liabilities 20.15 times.
- **Altman Z-score: 9.53**. A Z-score of 9.53 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Lakefront Biotherapeutics American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -10.7%** (YTD -12.9%, 3-mo 1.7%). The shares are down 10.7% over twelve months including dividends.
- **From 52-week high: -24.6%** (10.9% above the low). Trading 25% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 50**. An RSI of 50 is neutral.
- **Beta (1 yr): 0.59** (volatility 29%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LKFT · Page: https://foliofundamentals.com/stocks/lkft

Not investment advice.